PPPavel A. Popov

Pavel A. Popov

*This is an algorithmically generated author record based on publicly available information.

Pavel A. Popov has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical case of testicular serous papillary tumor with ovarian stroma

    by E. V. Grebenkin, A. A. Koshmelev, P. Monod, E. O. Baranova, P. A. Popov, D. P. Atayan, D. G. Pasechnik, K. A. Pavlov, M. Untesco, I. E. Shabanova, et al.

    Serous tumors are rare in the group of non-germ cell testicular tumors, ad are morphologically similar to serous ovarian tumors. Preoperative diagnosis of this tumor is difficult due to the lack of specific signs according to clinical and instrumental research methods. In turn, histological verification of a serous borderline tumor is also a difficult task and requires differential diagnosis, primarily with serous cystadenocarcinoma, which, unlike a serous borderline tumor, can metastasize and is generally characterized by worse prognosis. Immunohistochemical examination allows to exclude other tumors with a similar morphological structure, including mesothelial tumors. Due to the rare occurrence of testicular serous tumors, there is minimal clinical experience in the treatment of these tumors worldwide, and there is still no consensus on guidelines for their treatment. Radical orchiectomy is recommended for patients with border-line serous tumors.This article presents a clinical case of a testicular serous borderline papillary tumor with a discussion of the literature data on the instrumental, morphological, and immunohistochemical characteristics of this rare tumor in men.

  • Open Access

    Tumor cell-free DNA detection-based liquid biopsy of plasma and bile in pancreatic ductal adenocarcinoma: a pilot study

    by Mark Jain, David P. Atayan, Tagir I. Rakhmatullin, Tatyana E. Dakhtler, Pavel A. Popov, Pavel P. Kim, Julia V. Gontareva, Larisa M. Samokhodskaya, Vyacheslav I. Egorov, Armais A. Kamalov, et al.

    INTRODUCTION: Plasma liquid biopsy with tumor cell-free DNA detection is one of the most promising technologies in pancreatic ductal adenocarcinoma diagnosis. Due to low levels of this biomarker in plasma its detectability turns out to be lower than expected. However, some patients with this disease present with biliary obstruction, which enables collection of bile for tumor cell-free DNA analysis. THE AIM: To comparison of diagnostic potential of cell-free tumor DNA detection-based liquid biopsy of plasma and bile in pancreatic ductal adenocarcinoma patients. MATERIAL AND METHODS: The pilot study included 15 primary untreated pancreatic ductal adenocarcinoma patients with biliary obstruction. Cell-free DNA was isolated from 5 mL of plasma and 5 mL of bile. Tumor cell-free DNA detection was performed using digital droplet PCR with KRAS gene mutations analysis: G12A, G12C, G12D, G12R, G12S, G12V, G13D и Q61H (183AC), Q61H (183AT), Q61K, Q61L, Q61R. False-positive droplets threshold was established during the analysis of plasma cell-free DNA samples from 15 healthy volunteers. RESULTS: Tumor cell-free DNA was detected in 13 out of 15 bile samples, whereas among paired plasma samples only 9 were positive. All plasma positive samples had a paired positive bile sample. Tumor cell-free DNA levels were statistically significantly higher in bile than in plasma: 538.0 (4.11960.0) vs. 4.4 (027.6) copies/mL (p=0.005). CONCLUSION: Bile liquid biopsy in pancreatic ductal adenocarcinoma patients with biliary obstruction is a promising alternative to plasma analysis, due to higher concentrations of tumor cell-free DNA.